Omeros Corporation (OMER) Receives Consensus Rating of “Buy” from Brokerages
Omeros Corporation (NASDAQ:OMER) has received a consensus rating of “Buy” from the seven research firms that are currently covering the firm. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $39.50.
A number of equities research analysts have commented on OMER shares. FBR & Co reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Omeros Corporation in a research report on Wednesday, June 29th. Zacks Investment Research downgraded shares of Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Maxim Group reaffirmed a “buy” rating and issued a $30.00 target price on shares of Omeros Corporation in a research report on Thursday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 target price on shares of Omeros Corporation in a research report on Wednesday, August 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $56.00 target price (down previously from $62.00) on shares of Omeros Corporation in a research report on Thursday, August 11th.
Shares of Omeros Corporation (NASDAQ:OMER) traded up 2.4509% during midday trading on Monday, hitting $7.5199. The company had a trading volume of 3,543,098 shares. The stock has a 50 day moving average price of $10.60 and a 200 day moving average price of $11.73. The firm’s market capitalization is $295.48 million. Omeros Corporation has a 1-year low of $7.26 and a 1-year high of $16.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/omeros-corporation-omer-receives-consensus-rating-of-buy-from-brokerages.html
Omeros Corporation (NASDAQ:OMER) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.18. The company earned $10 million during the quarter, compared to the consensus estimate of $9.80 million. During the same period last year, the firm posted ($0.44) EPS. The company’s revenue for the quarter was up 212.5% on a year-over-year basis. On average, equities analysts anticipate that Omeros Corporation will post ($1.55) EPS for the current fiscal year.
In other news, VP Marcia S. Kelbon sold 16,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the sale, the vice president now owns 179,597 shares of the company’s stock, valued at approximately $1,959,403.27. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $11.56, for a total transaction of $183,804.00. Following the sale, the vice president now directly owns 179,497 shares of the company’s stock, valued at approximately $2,074,985.32. The disclosure for this sale can be found here. Insiders own 13.60% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Sheaff Brock Investment Advisors LLC purchased a new position in shares of Omeros Corporation during the second quarter valued at $105,000. Bourgeon Capital Management LLC purchased a new position in shares of Omeros Corporation during the second quarter valued at $158,000. BlackRock Advisors LLC increased its position in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares in the last quarter. Mesirow Financial Investment Management Equity Management purchased a new position in shares of Omeros Corporation during the second quarter valued at $244,000. Finally, Gradient Investments LLC increased its position in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares in the last quarter. 48.04% of the stock is owned by hedge funds and other institutional investors.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.